UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 28, 2005
Hana Biosciences, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 001-32626 | 84-1588441 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| | | |
400 Oyster Point Blvd., Ste. 215, South San Francisco, CA 94080
(Address of principal executive offices) (Zip Code)
(650) 588-6404
(Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
r Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
r Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
r Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
r Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
In its Current Report on Form 8-K filed on October 25, 2005, Hana Biosciences, Inc. (the “Company”) disclosed the completion of a private placement of 3,686,716 shares of its common stock and warrants to purchase an additional 737,343 shares of common stock. As of October 27, 2005, after giving effect to the issuance of the shares of common stock in the private placement, the Company had 22,168,366 shares of its common stock issued and outstanding.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | |
| | Hana Biosciences, Inc. |
|
|
|
| Date: October 28, 2005 | By: | /s/ Russell L. Skibsted |
| | Russell L. Skibsted |
| | Chief Financial Officer |
